Diabetes

Educational resources

eLearning module_Deep dive on SGLT2 inhibitors_index image

Deep dive on SGLT2 inhibitors with a focus on Jardiance® (empagliflozin)

Promotional material from the Boehringer Ingelheim and Lilly Diabetes Alliance

This eLearning module has been commissioned and funded by the Boehringer Ingelheim and Lilly Diabetes Alliance and developed in partnership with Guidelines in Practice and Guidelines Learning. Products are discussed.
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain or Northern Ireland
PC-GB-104397 April 2021

Trajenta webinar index

Dipeptidyl peptidase-4 inhibitors—still a major player in type 2 diabetes care

Commissioned by Boehringer Ingelheim Limited

This promotional webinar has been initiated and commissioned by Boehringer Ingelheim Limited and organised in partnership with Guidelines in Practice.
View Trajenta® (linagliptin) prescribing and adverse events reporting information for:
Great Britain 
Northern Ireland
PC-GB-103485 | July 2021

Index image

Guideline for the managed introduction of biosimilar bolus insulin in individuals with type 2 diabetes

Supported by an educational grant from Sanofi Ltd

This working party guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Sanofi Ltd

Steglatro FDG inxed image

Steglatro®▼ (Ertugliflozin)

Commissioned by MSD UK Ltd

This formulary decision guide was developed from content provided by MSD UK Ltd in a format developed by Guidelines in Practice.
View prescribing information and adverse event reporting
GB-STE-00433 | June 2021

FINAL index image

Trurapi▼ (insulin aspart 100 units/ml)

Commissioned by Sanofi Ltd

This formulary decision guide was developed from content provided by Sanofi Ltd in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
MAT-GB-2101070(v2.0) | Date of preparation: July 2021